AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02137811 — intervention group
Intervention type: OTHER
Intervention: MICK Assay
Description: An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
Study NCT02994680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three-burner LPG stove
Description: The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
Study NCT02994680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-burner LPG stove
Description: The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
Study NCT01589783 — intervention group
Intervention type: OTHER
Intervention: completion of a questionnaire
Description: Completion of a questionnaire
Study NCT01589783 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: A subset of 100 women will have a blood test to measure Vitamin D levels
Study NCT01247545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
Study NCT01247545 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered orally twice daily (bid).
Study NCT02994680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of LPG tanks
Description: One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
Study NCT02994680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers for LPG tanks
Description: One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 will be administered orally twice daily (bid).
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Description: HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
Study NCT03527147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5153
Description: AZD5153 will be administered orally once per day (qd).
Study NCT01765114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Formulation
Study NCT00925054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.001 mg/kg
Description: In Part 1, the planned starting dose levels is 0.001 mg/kg
Study NCT00925054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.003 mg/kg
Description: In Part 1, the planned starting dose levels is 0.003 mg/kg
Study NCT00925054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.01 mg/kg
Description: In Part 1, the planned starting dose levels is 0.01 mg/kg
Study NCT00925054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.03 mg/kg
Description: In Part 1, the planned starting dose levels is 0.03 mg/kg
Study NCT01772082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet mediated walking program
Study NCT01772082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mediated walking program
Study NCT00112229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 1
Description: Melan-A analog peptide + CpG + Montanide
Study NCT00112229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 2
Description: Melan-A natural peptide + CpG + Montanide
Study NCT01235598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
Study NCT01235598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP) 200 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study NCT00925054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.1 mg/kg
Description: In Part 1, the planned starting dose levels is 0.1 mg/kg
Study NCT00206583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Description: GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Study NCT01235598 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP) 200 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study NCT02550158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational program EDU-MICI
Study NCT02435602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NBI endoscopy
Description: GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
Study NCT05099822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97489
Description: Specified dose on specified days
Study NCT05099822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02167165 — intervention group
Intervention type: DRUG
Intervention: Digoxin Injection
Description: Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
Study NCT03128034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT03128034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03128034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03128034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT03128034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT03128034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03128034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pretargeted Radioimmunotherapy
Description: Given 211\^At-BC8-B10 IV
Study NCT03128034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00567762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Opthalmic suspension
Study NCT00567762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo eye drops
Study NCT02203448 — intervention group
Intervention type: DEVICE
Intervention: Facet Wedge spinal system
Study NCT01235598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP) 400 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study NCT02435602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lugol chromoendoscopy
Description: GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
Study NCT00112229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 3
Description: Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
Study NCT01182038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthRite birthing seat
Description: Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
Study NCT01235598 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP) 400 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study NCT04989153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pepsinogen
Description: serum pepsinogen diagnosed gastric cancer and precanceous lesion
Study NCT01638442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
Study NCT01750814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3102C
Description: a single dose (0.5 mL) intramuscularly on the deltoid muscle
Study NCT01750814 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC FLU inj.
Description: a single dose (0.5 mL) intramuscularly on the deltoid muscle
Study NCT00112229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 4
Description: Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
Study NCT02130713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third generation fluoroquinolone
Description: Prulifloxacin 600 mg
Study NCT02130713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement + third generation fluoroquinolone
Description: Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
Study NCT02835885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitmer High Voltage Stimulator model DS7A TENS unit
Study NCT02835885 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digitmer High Voltage Stimulator model DS7A TENS unit
Study NCT00786877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved biomass cookstove with exterior ventilation
Description: Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
Study NCT00786877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 intervention arm (LPG stove)
Description: LPG two burner stove with a 12 month supply of LP gas.
Study NCT01749384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01749384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01749384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01749384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT01638442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------
Study NCT03830905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221
Description: Participants will receive 200 mg XC221 once a day during 3 days
Study NCT03830905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo once a day during 3 days
Study NCT02942953 — intervention group
Intervention type: DEVICE
Intervention: Diaphragmatic Pacer
Description: The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
Study NCT02603224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-201
Description: Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
Study NCT01337037 — intervention group
Intervention type: DEVICE
Intervention: VATS lobectomy using modified equipments
Description: the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep.
Study NCT02603224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
Study NCT02961309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: 1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
Study NCT01337037 — intervention group
Intervention type: PROCEDURE
Intervention: VATS lobectomy using less staples
Description: VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (EVR)
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A (CyA)
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A (CyA)
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
Study NCT01337037 — intervention group
Intervention type: PROCEDURE
Intervention: Standard VATS lobectomy
Description: VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
Study NCT01337037 — intervention group
Intervention type: PROCEDURE
Intervention: Open lobectomy
Description: standard lobectomy procedure by thoracotomy approach
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (TAC)
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus (TAC)
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated mycophenolate sodium (EC-MPS)
Description: 180 mg or 360 mg tablet dosed 1440-2280 mg per day
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: 250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Study NCT00862979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Study NCT00537030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM
Study NCT00537030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00537030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03426241 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: this is cross-sectional study
Study NCT01981720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102 (pegunigalsidase alfa)
Description: PRX-102 1 mg/kg every 2 weeks
Study NCT01248104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Infusion during cardiac surgery
Study NCT01248104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminocaproic Acid
Description: Infusion during cardiac surgery
Study NCT04344847 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic sleeve gastrectomy
Description: Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
Study NCT04250064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Additional concurrent low-dose Bevacizumab with standard EBRT
Study NCT04250064 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose RT
Description: Ultra-low-dose EBRT instead of standard dose RT
Study NCT02936102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAZ053
Description: Anti-PD-L1 Antibody
Study NCT06461598 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle >= 1).
Study NCT01964755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Study NCT02936102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD-1 Antibody
Study NCT01964755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate administered starting on Day 2, per study protocol.